$NUVL

Meyers Michael L. sold (to issuer) 3,444 shares of NUVL

Meyers Michael L. sold (to issuer) 3,444 shares of Nuvalent, Inc. (NUVL) on 2026-07-15.

Original reporting
SEC EDGAR · Meyers Michael L.
Published Jul 15, 2026, 11:11 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 15, 2026, 11:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NUVL
Neutral
low confidence
Mentioned
$NUVL
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NUVLNeutralLow
01

Why it matters

Because the transaction price and total value are not disclosed and the share count is modest, the information is more useful for monitoring insider activity than for making a high-conviction trade.

02

Market read

Traders may note the insider sale, but the lack of disclosed economics and buyback-style framing suggests limited immediate market impact.

03

What to watch

No 10b5-1 plan is cited, but the transaction code and undisclosed price/value reduce interpretability; check for additional Form 4s around the same date for context.

Relevance 3/10Novelty 3/10Timing: Filed 2026-07-15, same day as the reported insider sale.

Background

The filing is an SEC Form 4 insider transaction for Nuvalent, Inc., reporting a director sale to the issuer.

Company-level read

Ticker impact

$NUVLNeutralLow confidence
Context

Nuvalent director Michael Meyers sold 3,444 shares to the issuer on 2026-07-15 under SEC Form 4, with price undisclosed.

Expected impact

Low near-term impact; any effect is likely sentiment-only unless follow-on filings show larger insider activity.

Evidence & confidence

The article is a routine Form 4 transaction with small share count and no disclosed transaction price or total value, and it does not indicate a change in business outlook.

Market effects

No clear sector read-through from a single director sale with no disclosed price/value.

None indicated.

None indicated.

Counterpoint

The sale is to the issuer, which can occur via buyback participation or planned liquidity, so it may not reflect bearish fundamentals.

Key entities

  • Nuvalent, Inc.

    Company whose director insider transaction is reported on SEC Form 4.

  • Michael L. Meyers

    Director who sold 3,444 shares to the issuer on 2026-07-15.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GSKMedAI 8/10

GSK completes acquisition of Nuvalent, Inc

GSK said it has completed its acquisition of Nuvalent (NASDAQ: NUVL) via a tender offer. The deal adds three lung cancer assets, including zidesamtinib (NVL-520) and neladalkib (NVL-655) under FDA review, plus NVL-330 in phase I. Transaction value is about $10.6B (£8.0B), net investment about $9.4B (£7.1B).

$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

$MUMed

More swings for AI stocks drag Wall Street back on the roller coaster

Wall Street swung as AI-related chip and memory stocks reversed after early gains. The S&P 500 fell 0.3% (7,386.65), the Nasdaq dropped 1% (25,678.82), and the Dow rose 0.2% (50,872.11). Micron slid 1.4% after a 10% drop; it had surged 9.9% Monday. Oil eased (Brent -3% to $91.45) but AI weakness outweighed. GSK agreed to buy Nuvalent for $10.6B, sending Nuvalent up 39.3%.

$COHRMed

Benzinga

U.S. stocks fell Tuesday as rotation out of chip and AI leaders resumed: Nasdaq 100 -3.3% to ~28,437, S&P 500 -1.6% to ~7,228, Dow -0.5% to ~50,535. Oil dropped ~6% and markets priced ~50% odds of a Fed hike by October ahead of Wednesday’s CPI. Tech led declines (XLK -5.1%); SMH fell as COHR -15.2%, MRVL -12.1%, LITE -11.8%.

$GSKHighAI 9/10

GSK Strikes $10.6B Nuvalent Deal Strengthening Targeting Cancer Pipeline

GSK agreed to acquire Nuvalent for $10.6B (£8.0B) to strengthen its late-stage oncology pipeline. GSK will tender for all Nuvalent shares at $124 cash, a 40% premium; net investment is $9.4B. Nuvalent’s FDA-review candidates Zidesamtinib and Neladalkib have 2026 decision dates. Deal expected to close in Q3 2026; GSK said 2026 outlook and 70p dividend remain unchanged.

$GSKHighAI 9/10

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10. 6 Billion For Cancer Drug Developer Nuvalent

GSK will acquire Nuvalent for $10.6 billion, buying all outstanding shares for $124 cash each, a 40% premium to Nuvalent’s last close of $88.49. Nuvalent shares rose about 39% in premarket. GSK expects revenue growth and accretion to sales and core operating profit from 2027, and higher core EPS from 2029, gaining lung cancer assets including zidesamtinib and neladalkib.